Neuronetics, Inc. (STIM) Bundle
An Overview of Neuronetics, Inc. (STIM)
General Summary of Neuronetics, Inc. (STIM)
Neuronetics, Inc. is a commercial-stage medical technology company focused on developing and commercializing neuroscience treatments. The company's primary product is NeuroStar Advanced Therapy System for treating major depressive disorder.
Company Products and Services
- NeuroStar TMS Therapy System
- Mental health treatment technologies
- Transcranial magnetic stimulation devices
Financial Performance Overview
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $159.4 million |
| Gross Profit | $97.2 million |
| Net Loss | $45.3 million |
Market Position
Neuronetics holds a significant market share in transcranial magnetic stimulation (TMS) technology, with approximately 70% of the TMS therapy market in the United States.
Key Performance Indicators
| Metric | 2023 Data |
|---|---|
| NeuroStar Systems Installed | 1,400+ healthcare facilities |
| Patient Treatments | Over 1.5 million treatments delivered |
Company Operational Highlights
- Publicly traded on NASDAQ under ticker STIM
- Headquartered in Malvern, Pennsylvania
- Founded in 2002
Mission Statement of Neuronetics, Inc. (STIM)
Mission Statement of Neuronetics, Inc. (STIM)
Neuronetics, Inc. mission statement focuses on advancing mental health treatment through innovative neuromodulation technologies.
Core Components of Mission Statement
| Component | Specific Details | Quantitative Metrics |
|---|---|---|
| Treatment Innovation | NeuroStar Advanced Therapy TMS Platform | FDA-cleared for Major Depressive Disorder in 2008 |
| Clinical Effectiveness | Non-invasive brain stimulation technology | Over 4.4 million treatments performed as of 2023 |
| Patient Access | Expanding mental health treatment options | Available in 1,500+ treatment centers nationwide |
Key Technology Focus Areas
- Transcranial Magnetic Stimulation (TMS)
- Depression treatment solutions
- Neurological disorder interventions
Financial Performance Indicators
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $159.4 million |
| R&D Expenditure | $41.2 million |
| Market Capitalization | Approximately $360 million |
Clinical Impact Statistics
- 65% patient response rate in depression treatment
- 40% patient remission rate using NeuroStar technology
- FDA-cleared for treatment-resistant depression
Neuronetics continues to prioritize technological advancement in mental health treatment through precision neuromodulation solutions.
Vision Statement of Neuronetics, Inc. (STIM)
Vision Statement of Neuronetics, Inc. (STIM) in 2024
Core Vision FrameworkNeuronetics, Inc. focuses on advancing neuromodulation technologies for mental health treatment, specifically targeting treatment-resistant conditions.
| Vision Dimension | Specific Focus |
|---|---|
| Technological Innovation | Advanced transcranial magnetic stimulation (TMS) platforms |
| Market Segment | Psychiatric and neurological disorders treatment |
| Patient Reach | Expanding access to non-invasive neurological treatments |
Strategic Vision Components
Treatment Expansion Objectives- Develop next-generation TMS technologies
- Expand clinical applications beyond depression
- Improve patient outcomes through precision neurostimulation
Market Position and Growth Strategy
Neuronetics aims to maintain leadership in neuromodulation with NeuroStar TMS Therapy system, targeting:
| Metric | 2024 Target |
|---|---|
| Market Share | Approximately 65% in TMS therapy market |
| Revenue Projection | $75-85 million |
| Clinical Deployment | Over 1,200 healthcare facilities |
Research and Development Focus
Key R&D Priorities- Enhance NeuroStar Advanced Therapy platform
- Explore new neurological disorder treatments
- Improve treatment personalization algorithms
Core Values of Neuronetics, Inc. (STIM)
Core Values of Neuronetics, Inc. (STIM) in 2024
Patient-Centric InnovationNeuronetics demonstrates commitment to patient-centric innovation through its TMS therapy platform. In 2023, the company reported 215,000 total patient treatments using NeuroStar Advanced Therapy.
| Metric | 2023 Performance |
|---|---|
| Total Patient Treatments | 215,000 |
| TMS Therapy Centers | 1,400+ |
Neuronetics invests significantly in clinical research and development.
- R&D Expenditure in 2023: $21.4 million
- Clinical studies published: 7 peer-reviewed publications
- FDA-cleared medical devices: 2 platforms
Financial transparency is demonstrated through detailed reporting.
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $159.3 million |
| Gross Margin | 65.4% |
Neuronetics partners with multiple healthcare networks and providers.
- Healthcare Provider Partnerships: 250+
- Mental Health Clinics Utilizing Technology: 1,100
Investment in employee training and development.
- Annual Training Hours per Employee: 40
- Employee Retention Rate: 87%
Neuronetics, Inc. (STIM) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.